[Are the short-acting insulin analogs superfluous?].
Arand
Manuela
M
D003362:Cost-Benefit Analysis; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000191:economics; D005858:Germany; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D007328:Insulin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000191:economics / Q000627:therapeutic use; D011788:Quality of Life; D013997:Time Factors
D007004:Hypoglycemic Agents; D007328:Insulin